Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

See Additional file 3: Appendix Table S3 and Additional file 4: Appendix Table S4.Associations between listing of CKD on problem list with guideline-driven processes of careaOutcomeModel 1Model 2Problem List CKD Albuminuria test ordered Odds RatioOdds RatioN (%)(95% C.I.)(95% C.I.) No = 932288 (30%) Ref Ref Yes = 679472 (57%)2.94 (2.39 to 3.62) †2.83 (2.17 to 3.70) †Problem List CKD Parathyroid hormone test ordered No = 932109 (12%) Ref Ref Yes = 679400 (49%)6.94 (5.40 to 8.92) †5.03 (3.87 to 6.54) †Problem List CKD Phosphorus test ordered No = 932484 (51%) Ref Ref Yes = 679601 (73%)2.24 (1.81 to 2.77) †1.60 (1.27 to 2.01) †Problem List CKD Vitamin D test ordered No = 932446 47% Ref Ref Yes = 679573 70%2.66 (2.16 to 3.27) †2.35 (1.88 to 2.93) †Problem List CKD ACE/ARB prescription No = 932543 (57%) Ref Ref Yes = 679570 (69%)1.63 (1.32 to 2.01) †1.21 (0.94 to 1.55) †Problem List CKD Statin prescription No = 932565 (60%) Ref Ref Yes = 679600 (73%)1.91 (1.53 to 2.37) †1.56 (1.21 to 2.02) †aCharacteristics of patients included in process of care analyes, based on data from 01/01/2014 to 12/31/2015Model 1 includes age, sex, race, and ethnicityModel 2 adds each patient’s earliest 2nd qualifying eGFR (15 to 59.999 mL/min/1.73 m2) and comorbidities (diabetes mellitus, cerebrovascular disease, congestive heart failure, hypertension, and coronary artery disease)† = p < 0.05

Source: Guideline-driven care CKD sub-cohort. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We define this as the overall CKD cohort, and it was created by identifying patients aged 18 to 80 with at least two serum creatinine measurements at least 90 days apart.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Validating laboratory defined chronic kidney disease in the electronic health record for patients in primary care

Study design awaiting verification · BMC Nephrology · 2019

Original publication title

Validating laboratory defined chronic kidney disease in the electronic health record for patients in primary care

Martin Frigaard; Anna Rubinsky; Lo Lowell; Anna Malkina; Leah Karliner; Michael Kohn; Carmen A Peralta

© The Author(s). 2019

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Identifying CKD status by historical eGFRs overestimates disease prevalence. A CKD diagnosis in the patient chart was a reasonable surrogate for provider awareness of disease status, but CKD awareness remains relatively low. CKD in the patient chart was associated with higher rates of albuminuria testing and use of statins, but not use of ACE/ARB.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Electronic health record (EHR) data is increasingly used to identify patients with chronic kidney disease (CKD). EHR queries used to capture CKD status, identify comorbid conditions, measure awareness by providers, and track adherence to guideline-concordant processes of care have not been validated.

Source: Background

Abstract: What methods does the paper describe?

We extracted EHR data for primary-care patients with two eGFRcreat 15-59 mL/min/1.73 m^2 at least 90 days apart. Two nephrologists manually reviewed a random sample of 50 charts to determine CKD status, associated comorbidities, and physician awareness of CKD. We also assessed the documentation of a CKD diagnosis with guideline-driven care.

Source: Methods

Abstract: Electronic supplementary material

The online version of this article (10.1186/s12882-018-1156-2) contains supplementary material, which is available to authorized users.

Source: Electronic supplementary material

Abstract: Results

Complete data were available on 1767 patients with query-defined CKD of whom 822 (47%) had a CKD diagnosis in their chart. Manual chart review confirmed the CKD diagnosis in 34 or 50 (68%) patients. Agreement between the reviewers and the EHR diagnoses on the presence of comorbidities was good (κ > 0.70, p < 0.05), except for congestive heart failure, (κ = 0.45, p < 0.05). Reviewers felt the providers were aware of CKD in 23 of 34 (68%) of the confirmed CKD cases.

A CKD diagnosis was associated with higher odds of guideline-driven care including CKD-specific laboratory tests and prescriptions for statins. After adjustment, CKD diagnosis documentation was not significantly associated with ACE/ARB prescription.

Source: Results

Abstract: Conclusions

Identifying CKD status by historical eGFRs overestimates disease prevalence. A CKD diagnosis in the patient chart was a reasonable surrogate for provider awareness of disease status, but CKD awareness remains relatively low. CKD in the patient chart was associated with higher rates of albuminuria testing and use of statins, but not use of ACE/ARB.

Source: Conclusions
Authors’ abstract

Background

Electronic health record (EHR) data is increasingly used to identify patients with chronic kidney disease (CKD). EHR queries used to capture CKD status, identify comorbid conditions, measure awareness by providers, and track adherence to guideline-concordant processes of care have not been validated.

Methods

We extracted EHR data for primary-care patients with two eGFRcreat 15-59 mL/min/1.73 m^2 at least 90 days apart. Two nephrologists manually reviewed a random sample of 50 charts to determine CKD status, associated comorbidities, and physician awareness of CKD. We also assessed the documentation of a CKD diagnosis with guideline-driven care.

Results

Complete data were available on 1767 patients with query-defined CKD of whom 822 (47%) had a CKD diagnosis in their chart. Manual chart review confirmed the CKD diagnosis in 34 or 50 (68%) patients. Agreement between the reviewers and the EHR diagnoses on the presence of comorbidities was good (κ > 0.70, p < 0.05), except for congestive heart failure, (κ = 0.45, p < 0.05). Reviewers felt the providers were aware of CKD in 23 of 34 (68%) of the confirmed CKD cases.

A CKD diagnosis was associated with higher odds of guideline-driven care including CKD-specific laboratory tests and prescriptions for statins. After adjustment, CKD diagnosis documentation was not significantly associated with ACE/ARB prescription.

Conclusions

Identifying CKD status by historical eGFRs overestimates disease prevalence. A CKD diagnosis in the patient chart was a reasonable surrogate for provider awareness of disease status, but CKD awareness remains relatively low. CKD in the patient chart was associated with higher rates of albuminuria testing and use of statins, but not use of ACE/ARB.

Electronic supplementary material

The online version of this article (10.1186/s12882-018-1156-2) contains supplementary material, which is available to authorized users.

Publication and source details

Original title: Validating laboratory defined chronic kidney disease in the electronic health record for patients in primary care

Martin Frigaard; Anna Rubinsky; Lo Lowell; Anna Malkina; Leah Karliner; Michael Kohn; Carmen A Peralta

BMC Nephrology · 2019

© The Author(s). 2019https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/100001259National Kidney FoundationP0515917Peralta Carmen A

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T18:48:21.504274+00:00

DOI: 10.1186/s12882-018-1156-2 · PMC6318865